文献速递外周动脉疾病血液透析通路

外周动脉疾病患者接受 deceased donor 肾移植的生存获益

Survival Benefit of Deceased Donor Kidney Transplantation among Patients with Peripheral Artery Disease.
PubMed 文献 · Ann Vasc Surg · 2025-07-09

基于 SRTR 2003–2022 年 506,785 例成人肾移植等待者数据,8.7% 合并 PAD、36.0% 接受 DDKT。中位随访 3.21 年后,无论 PAD 状态,DDKT 较继续等待均显著降低死亡风险(校正 HR 0.45–0.60,P<0.001),PAD 不应视为 DDKT 绝对禁忌。

要点

  • 合并 PAD 的肾移植等待者接受 DDKT 较继续等待死亡风险显著降低(校正 HR 0.45–0.60,P<0.001)。
  • 按性别、种族和糖尿病状态分层后,DDKT 的生存获益未见实质性改变。
  • PAD 不应作为 deceased donor 肾移植的绝对禁忌证。

核心结论

  • 在 SRTR 数据库中将 PAD 二分类后,合并与不合并 PAD 的等待者接受 DDKT 较继续等待均获得相似的长期生存获益。
  • PAD 不应成为 deceased donor 肾移植的绝对禁忌证。

研究设计与样本

  • 共 506,785 例成人肾移植等待者,8.7% 合并 PAD,36.0% 接受 DDKT。
  • 采用 Kaplan-Meier 生存估计和多变量 Cox 比例风险模型,按 PAD 状态分层比较接受 DDKT 与继续等待者的死亡风险。

主要发现

  • 中位随访 3.21 年(IQR 1.11–7.03 年),死亡率随 DDKT 和 PAD 状态显著不同。
  • 校正基线差异后,无论 PAD 状态,DDKT 较继续等待均与显著更低的死亡风险相关(校正 HR 0.45–0.60,P<0.001)。
  • 按性别、种族和民族、糖尿病状态进一步分层未实质性改变上述结果。

关键数值与推荐

  • DDKT 较继续等待的校正死亡风险比范围为 0.45–0.60,P<0.001,适用于合并与不合并 PAD 的等待者。

临床怎么用

  • 对于合并 PAD 的 deceased donor 肾移植等待者,不应仅因 PAD 诊断而排除移植。
  • 移植决策时应结合 PAD 的具体疾病谱和严重程度进行个体化评估。

局限性

  • SRTR 数据库将 PAD 二分类捕捉,可能未充分反映 PAD 疾病谱的异质性。
  • 研究为回顾性观察性设计,可能存在残余混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Peripheral artery disease (PAD) is a common comorbidity among patients waitlisted for deceased donor kidney transplant (DDKT). However, some centers consider PAD a contraindication for transplant given the higher risk of postoperative complications. We aimed to examine the survival benefit of DDKT among patients with and without PAD. METHODS: We used data from the Scientific Registry of Transplant Recipients (SRTR) from January 2003 to December 2022 to identify all DDKT waitlist candidates. Kaplan-Meier survival estimates and multivariable Cox proportional hazards models were used to compare patient mortality for those who received a DDKT versus those remaining on the waitlist, stratified by PAD status. RESULTS: Overall, 506,785 candidates were listed for adult kidney-only transplant during the study period, of which 8.7% had PAD and 36.0% received a DDKT. After a median follow-up time of 3.21 years from waitlist activation [interquartile range 1.11-7.03 years], mortality varied significantly according to DDKT and PAD status. After adjusting for baseline differences, DDKT was associated with a significantly lower hazard of death compared to remaining on the waitlist, regardless of PAD status [adjusted hazards ratio 0.45-0.60, P < 0.001]. Further stratifying by sex, race and ethnicity, and diabetes status did not substantially alter these results. CONCLUSION: PAD includes a spectrum of diseases with varying mortality risks. As captured and dichotomized in the SRTR database, DDKT conferred a similar long-term benefit relative to remaining on the waitlist for candidates with and without PAD. Therefore, PAD should not be an absolute contraindication to DDKT.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Tan LT, Kernodle AB, Yu S, et al. Survival Benefit of Deceased Donor Kidney Transplantation among Patients with Peripheral Artery Disease. Ann Vasc Surg. 2025. PMID: 40645573. doi:10.1016/j.avsg.2025.07.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。